Search

Your search keyword '"Shpilberg, Ofer"' showing total 1,049 results
Start Over Author "Shpilberg, Ofer"
1,049 results on '"Shpilberg, Ofer"'

1. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Author

Dreyling, Martin, Doorduijn, Jeanette, Giné, Eva, Jerkeman, Mats, Walewski, Jan, Hutchings, Martin, Mey, Ulrich, Riise, Jon, Trneny, Marek, Vergote, Vibeke, Shpilberg, Ofer, Gomes da Silva, Maria, Leppä, Sirpa, Jiang, Linmiao, Stilgenbauer, Stephan, Kerkhoff, Andrea, Jachimowicz, Ron D, Celli, Melania, Hess, Georg, Arcaini, Luca, Visco, Carlo, van Meerten, Tom, Wirths, Stefan, Zinzani, Pier Luigi, Novak, Urban, Herhaus, Peter, Benedetti, Fabio, Sonnevi, Kristina, Hanoun, Christine, Hänel, Matthias, Dierlamm, Judith, Pott, Christiane, Klapper, Wolfram, Gözel, Döndü, Schmidt, Christian, Unterhalt, Michael, Ladetto, Marco, and Hoster, Eva

Published
2024
Full Text
View/download PDF

4. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy

Author

Friedman, Joshua S., primary, Durham, Benjamin H., additional, Reiner, Anne S., additional, Yabe, Mariko, additional, Petrova‐Drus, Kseniya, additional, Dogan, Ahmet, additional, Pulitzer, Melissa, additional, Busam, Klaus J., additional, Francis, Jasmine H., additional, Rampal, Raajit K., additional, Ulaner, Gary A., additional, Reddy, Ryan, additional, Yeh, Randy, additional, Hatzoglou, Vaios, additional, Lacouture, Mario E., additional, Rotemberg, Veronica, additional, Mazor, Roei D., additional, Hershkovitz‐Rokah, Oshrat, additional, Shpilberg, Ofer, additional, Goyal, Gaurav, additional, Go, Ronald S., additional, Abeykoon, Jithma P., additional, Rech, Karen, additional, Morlote, Diana, additional, Fidai, Shiraz, additional, Gannamani, Vedavyas, additional, Zia, Maryam, additional, Abdel‐Wahab, Omar, additional, Panageas, Katherine S., additional, Rosenblum, Marc K., additional, and Diamond, Eli L., additional

Published
2024
Full Text
View/download PDF

6. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Jr., Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Jr., Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, Jr., MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, and Windsor, Kevin

Published
2022
Full Text
View/download PDF

7. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

Author

Cohen, Yael C., Zada, Mor, Wang, Shuang-Yin, Bornstein, Chamutal, David, Eyal, Moshe, Adi, Li, Baoguo, Shlomi-Loubaton, Shir, Gatt, Moshe E., Gur, Chamutal, Lavi, Noa, Ganzel, Chezi, Luttwak, Efrat, Chubar, Evgeni, Rouvio, Ory, Vaxman, Iuliana, Pasvolsky, Oren, Ballan, Mouna, Tadmor, Tamar, Nemets, Anatoly, Jarchowcky-Dolberg, Osnat, Shvetz, Olga, Laiba, Meirav, Shpilberg, Ofer, Dally, Najib, Avivi, Irit, Weiner, Assaf, and Amit, Ido

Published
2021
Full Text
View/download PDF

8. Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

Author

Doe-Tetteh, Seyram A., primary, Camp, Sabrina Y., primary, Reales, Dalicia, primary, Crowdis, Jett, primary, Noronha, Anne Marie, primary, Wolff, Bernadette, primary, Alano, Tina, primary, Galle, Jesse, primary, Selcuklu, S. Duygu, primary, Viale, Agnes, primary, Socci, Nicholas D., primary, Liu, Ying L., primary, Tew, William P., primary, Aghajanian, Carol, primary, Ladanyi, Marc, primary, He, Meng Xiao, primary, AlDubayan, Saud H., primary, Mazor, Roei David, primary, Shpilberg, Ofer, primary, Hershkovitz-Rokah, Oshrat, primary, Riancho, Jose A., primary, Hernandez, Jose L., primary, Gonzalez-Vela, M. Carmen, primary, Buthorn, Justin J., primary, Wilson, Manda, primary, Webber, Amy E., primary, Yabe, Mariko, primary, Petrova-Drus, Kseniya, primary, Rosenblum, Marc, primary, Durham, Benjamin H., primary, Abdel-Wahab, Omar, primary, Berger, Michael F., primary, Donoghue, Mark T.A., primary, Kung, Andrew L., primary, Glade Bender, Julia, primary, Shukla, Neerav N., primary, Funt, Samuel A., primary, Dogan, Ahmet, primary, Soslow, Robert A., primary, Al-Ahmadie, Hikmat, primary, Feldman, Darren R., primary, Van Allen, Eliezer M., primary, Diamond, Eli L., primary, and Solit, David B., primary

Published
2023
Full Text
View/download PDF

9. Data from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

Author

Doe-Tetteh, Seyram A., primary, Camp, Sabrina Y., primary, Reales, Dalicia, primary, Crowdis, Jett, primary, Noronha, Anne Marie, primary, Wolff, Bernadette, primary, Alano, Tina, primary, Galle, Jesse, primary, Selcuklu, S. Duygu, primary, Viale, Agnes, primary, Socci, Nicholas D., primary, Liu, Ying L., primary, Tew, William P., primary, Aghajanian, Carol, primary, Ladanyi, Marc, primary, He, Meng Xiao, primary, AlDubayan, Saud H., primary, Mazor, Roei David, primary, Shpilberg, Ofer, primary, Hershkovitz-Rokah, Oshrat, primary, Riancho, Jose A., primary, Hernandez, Jose L., primary, Gonzalez-Vela, M. Carmen, primary, Buthorn, Justin J., primary, Wilson, Manda, primary, Webber, Amy E., primary, Yabe, Mariko, primary, Petrova-Drus, Kseniya, primary, Rosenblum, Marc, primary, Durham, Benjamin H., primary, Abdel-Wahab, Omar, primary, Berger, Michael F., primary, Donoghue, Mark T.A., primary, Kung, Andrew L., primary, Glade Bender, Julia, primary, Shukla, Neerav N., primary, Funt, Samuel A., primary, Dogan, Ahmet, primary, Soslow, Robert A., primary, Al-Ahmadie, Hikmat, primary, Feldman, Darren R., primary, Van Allen, Eliezer M., primary, Diamond, Eli L., primary, and Solit, David B., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

Author

Doe-Tetteh, Seyram A., primary, Camp, Sabrina Y., primary, Reales, Dalicia, primary, Crowdis, Jett, primary, Noronha, Anne Marie, primary, Wolff, Bernadette, primary, Alano, Tina, primary, Galle, Jesse, primary, Selcuklu, S. Duygu, primary, Viale, Agnes, primary, Socci, Nicholas D., primary, Liu, Ying L., primary, Tew, William P., primary, Aghajanian, Carol, primary, Ladanyi, Marc, primary, He, Meng Xiao, primary, AlDubayan, Saud H., primary, Mazor, Roei David, primary, Shpilberg, Ofer, primary, Hershkovitz-Rokah, Oshrat, primary, Riancho, Jose A., primary, Hernandez, Jose L., primary, Gonzalez-Vela, M. Carmen, primary, Buthorn, Justin J., primary, Wilson, Manda, primary, Webber, Amy E., primary, Yabe, Mariko, primary, Petrova-Drus, Kseniya, primary, Rosenblum, Marc, primary, Durham, Benjamin H., primary, Abdel-Wahab, Omar, primary, Berger, Michael F., primary, Donoghue, Mark T.A., primary, Kung, Andrew L., primary, Glade Bender, Julia, primary, Shukla, Neerav N., primary, Funt, Samuel A., primary, Dogan, Ahmet, primary, Soslow, Robert A., primary, Al-Ahmadie, Hikmat, primary, Feldman, Darren R., primary, Van Allen, Eliezer M., primary, Diamond, Eli L., primary, and Solit, David B., primary

Published
2023
Full Text
View/download PDF

11. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

Author

O'Brien, Susan, Schiller, Gary, Lister, John, Damon, Lloyd, Goldberg, Stuart, Aulitzky, Walter, Ben-Yehuda, Dina, Stock, Wendy, Coutre, Steven, Douer, Dan, Heffner, Leonard T, Larson, Melissa, Seiter, Karen, Smith, Scott, Assouline, Sarit, Kuriakose, Philip, Maness, Lori, Nagler, Arnon, Rowe, Jacob, Schaich, Markus, Shpilberg, Ofer, Yee, Karen, Schmieder, Guenter, Silverman, Jeffrey A, Thomas, Deborah, Deitcher, Steven R, and Kantarjian, Hagop

Subjects
Philadelphia Chromosome, Humans, Nervous System Diseases, Neutropenia, Recurrence, Constipation, Vincristine, Antineoplastic Agents, Phytogenic, Liposomes, Treatment Outcome, Remission Induction, Injections, Intravenous, Drug Administration Schedule, Survival Analysis, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Clinical Trials and Supportive Activities, Clinical Research, Cancer, Hematology, Pediatric, Childhood Leukemia, Orphan Drug, Pediatric Cancer, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeRelapsed adult acute lymphoblastic leukemia (ALL) is associated with high reinduction mortality, chemotherapy resistance, and rapid progression leading to death. Vincristine sulfate liposome injection (VSLI), sphingomyelin and cholesterol nanoparticle vincristine (VCR), facilitates VCR dose-intensification and densification plus enhances target tissue delivery. We evaluated high-dose VSLI monotherapy in adults with Philadelphia chromosome (Ph) -negative ALL that was multiply relapsed, relapsed and refractory to reinduction, and/or relapsed after hematopoietic cell transplantation (HCT).Patients and methodsSixty-five adults with Ph-negative ALL in second or greater relapse or whose disease had progressed following two or more leukemia therapies were treated in this pivotal phase II, multinational trial. Intravenous VSLI 2.25 mg/m(2), without dose capping, was administered once per week until response, progression, toxicity, or pursuit of HCT. The primary end point was achievement of complete response (CR) or CR with incomplete hematologic recovery (CRi).ResultsThe CR/CRi rate was 20% and overall response rate was 35%. VSLI monotherapy was effective as third-, fourth-, and fifth-line therapy and in patients refractory to other single- and multiagent reinduction therapies. Median CR/CRi duration was 23 weeks (range, 5 to 66 weeks); 12 patients bridged to a post-VSLI HCT, and five patients were long-term survivors. VSLI was generally well tolerated and associated with a low 30-day mortality rate (12%).ConclusionHigh-dose VSLI monotherapy resulted in meaningful clinical outcomes including durable responses and bridging to HCT in advanced ALL settings. The toxicity profile of VSLI was predictable, manageable, and comparable to standard VCR despite the delivery of large, normally unachievable, individual and cumulative doses of VCR.

Published
2013

12. Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis

Author

Vidal, Liat, Gafter-Gvili, Anat, Salles, Gilles, Bousseta, Sami, Oberman, Bernice, Rubin, Carmit, van Oers, Marinus H.J., Fortpied, Catherine, Ghielmini, Michele, Pettengell, Ruth, Witzens-Harig, Mathias, Dreger, Peter, Vitolo, Umberto, Gomes da Silva, Maria, Evangelista, Andrea, Li, Hailun, Freedman, Laurence, Habermann, Thomas M., and Shpilberg, Ofer

Published
2017
Full Text
View/download PDF

13. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Author

Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Weisel, Katja, San-Miguel, Jesus, Shpilberg, Ofer, Grosicki, Sebastian, Špička, Ivan, Walter-Croneck, Adam, Magen, Hila, Mateos, Maria-Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Spencer, Andrew, Oakervee, Heather, Orlowski, Robert Z., Taniwaki, Masafumi, Röllig, Christoph, Einsele, Hermann, Matsumoto, Morio, Wu, Ka Lung, Anderson, Kenneth C., Jou, Ying-Ming, Ganetsky, Alex, Singhal, Anil K., and Richardson, Paul G.

Published
2020
Full Text
View/download PDF

14. Supplementary Table 2 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 3 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 1 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 2 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 3 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table 4 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Methods from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Author

Coiffier, Bertrand, primary, Li, Weimin, primary, Henitz, Erin D., primary, Karkera, Jayaprakash D., primary, Favis, Reyna, primary, Gaffney, Dana, primary, Shapiro, Alice, primary, Theocharous, Panteli, primary, Elsayed, Yusri A., primary, van de Velde, Helgi, primary, Schaffer, Michael E., primary, Osmanov, Evgenii A., primary, Hong, Xiaonan, primary, Scheliga, Adriana, primary, Mayer, Jiri, primary, Offner, Fritz, primary, Rule, Simon, primary, Teixeira, Adriana, primary, Romejko-Jarosinska, Joanna, primary, de Vos, Sven, primary, Crump, Michael, primary, Shpilberg, Ofer, primary, Zinzani, Pier Luigi, primary, Cakana, Andrew, primary, Esseltine, Dixie-Lee, primary, Mulligan, George, primary, and Ricci, Deborah, primary

Published
2023
Full Text
View/download PDF

22. Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach

Author

Doe-Tetteh, Seyram A., primary, Camp, Sabrina Y., additional, Reales, Dalicia, additional, Crowdis, Jett, additional, Noronha, Anne Marie, additional, Wolff, Bernadette, additional, Alano, Tina, additional, Galle, Jesse, additional, Selcuklu, S. Duygu, additional, Viale, Agnes, additional, Socci, Nicholas D., additional, Liu, Ying L., additional, Tew, William P., additional, Aghajanian, Carol, additional, Ladanyi, Marc, additional, He, Meng Xiao, additional, AlDubayan, Saud H., additional, Mazor, Roei David, additional, Shpilberg, Ofer, additional, Hershkovitz-Rokah, Oshrat, additional, Riancho, Jose A., additional, Hernandez, Jose L., additional, Gonzalez-Vela, M. Carmen, additional, Buthorn, Justin J., additional, Wilson, Manda, additional, Webber, Amy E., additional, Yabe, Mariko, additional, Petrova-Drus, Kseniya, additional, Rosenblum, Marc, additional, Durham, Benjamin H., additional, Abdel-Wahab, Omar, additional, Berger, Michael F., additional, Donoghue, Mark T.A., additional, Kung, Andrew L., additional, Glade Bender, Julia, additional, Shukla, Neerav N., additional, Funt, Samuel A., additional, Dogan, Ahmet, additional, Soslow, Robert A., additional, Al-Ahmadie, Hikmat, additional, Feldman, Darren R., additional, Van Allen, Eliezer M., additional, Diamond, Eli L., additional, and Solit, David B., additional

Published
2023
Full Text
View/download PDF

25. Mutant PIK3CAis a targetable driver alteration in histiocytic neoplasms

Author

Durham, Benjamin H., Hershkovitz-Rokah, Oshrat, Abdel-Wahab, Omar, Yabe, Mariko, Chung, Young Rock, Itchaki, Gilad, Ben-Sasson, Maayan, Asher-Guz, Vered A., Groshar, David, Doe-Tetteh, Seyram A., Alano, Tina, Solit, David B., Shpilberg, Ofer, Diamond, Eli L., and Mazor, Roei D.

Abstract

•Activation of PI3K signaling is sufficient to induce a histiocytosis-like disease in vivo at the monocyte/dendritic cell precursor level.•The PI3Kα-specific inhibitor alpelisib shows promising clinical efficacy in PIK3CA-mutant LCH.

Published
2023
Full Text
View/download PDF

29. Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Author

Cohen, Yael C, primary, Gatt, Moshe E, additional, Luttwak, Efrat, additional, Lavi, Noa, additional, Ganzel, Chezi, additional, Chubar, Evgeni, additional, Rouvio, Ory, additional, Vaxman, Iuliana, additional, Pasvolsky, Oren, additional, Ballan, Mouna, additional, Tadmor, Tamar, additional, Nemets, Anatoly, additional, Jarchowsky, Osnat, additional, Shvetz, Olga, additional, Shpilberg, Ofer, additional, Dally, Najib, additional, Leiba, Merav, additional, Weiner, Assaf, additional, Zada, Mor, additional, Wang, Shuang-Yin, additional, Gur, Chamutal, additional, Lowenton-Spier, Noa, additional, Goor-Porges, Liron, additional, Amit, Ido, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

30. Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Author

Dreyling, Martin, primary, Doorduijn, Jeanette K., additional, Gine, Eva, additional, Jerkeman, Mats, additional, Walewski, Jan, additional, Hutchings, Martin, additional, Mey, Ulrich, additional, Riise, Jon, additional, Trneny, Marek, additional, Vergote, Vibeke K.J., additional, Celli, Melania, additional, Shpilberg, Ofer, additional, Gomes da Silva, Maria, additional, Leppa, Sirpa, additional, Jiang, Linmiao, additional, Pott, Christiane, additional, Klapper, Wolfram, additional, Gözel, Döndü, additional, Schmidt, Christian, additional, Unterhalt, Michael, additional, Ladetto, Marco, additional, and Hoster, Eva, additional

Published
2022
Full Text
View/download PDF

42. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth

Author

Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Palumbo, Antonio, San‐Miguel, Jesus, Shpilberg, Ofer, Anderson, Kenneth, Grosicki, Sebastian, Spicka, Ivan, Walter‐Croneck, Adam, Magen, Hila, Mateos, Maria‐Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Bleickardt, Eric, Poulart, Valerie, Sheng, Jennifer, Sy, Oumar, Katz, Jessica, Singhal, Anil, and Richardson, Paul

Published
2017
Full Text
View/download PDF

43. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients

Author

Dann, Eldad J., Bairey, Osnat, Bar‐Shalom, Rachel, Mashiach, Tanya, Barzilai, Elinor, Kornberg, Abraham, Akria, Luiza, Tadmor, Tamar, Filanovsky, Kalman, Abadi, Uri, Kagna, Olga, Ruchlemer, Rosa, Abdah‐Bortnyak, Roxolyana, Goldschmidt, Neta, Epelbaum, Ron, Horowitz, Netanel A., Lavie, David, Ben‐Yehuda, Dina, Shpilberg, Ofer, and Paltiel, Ora

Published
2017
Full Text
View/download PDF

44. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia

Author

Robak, Tadeusz, Windyga, Jerzy, Trelinski, Jacek, von Depka Prondzinski, Mario, Giagounidis, Aristoteles, Doyen, Chantal, Janssens, Ann, Álvarez-Román, María Teresa, Jarque, Isidro, Loscertales, Javier, Rus, Gloria Pérez, Hellmann, Andrzej, Jêdrzejczak, Wiesław Wiktor, Kuliczkowski, Kazimierz, Golubovic, Lana M., Celeketic, Dusica, Cucuianu, Andrei, Gheorghita, Emanuil, Lazaroiu, Mihaela, Shpilberg, Ofer, Attias, Dina, Karyagina, Elena, Svetlana, Kalinina, Vilchevska, Kateryna, Cooper, Nichola, Talks, Kate, Prabhu, Mukhyaprana, Sripada, Prasad, Bharadwaj, T.P.R., Næsted, Henrik, Skartved, Niels J.Ø., Frandsen, Torben P., Flensburg, Mimi F., Andersen, Peter S., and Petersen, Jørgen

Published
2012
Full Text
View/download PDF

47. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Author

Pfreundschuh, Michael, Kuhnt, Evelyn, Trümper, Lorenz, Österborg, Anders, Trneny, Marek, Shepherd, Lois, Gill, Devinder S, Walewski, Jan, Pettengell, Ruth, Jaeger, Ulrich, Zinzani, Pier-Luigi, Shpilberg, Ofer, Kvaloy, Stein, de Nully Brown, Peter, Stahel, Rolf, Milpied, Noel, López-Guillermo, Armando, Poeschel, Viola, Grass, Sandra, Loeffler, Markus, and Murawski, Niels

Published
2011
Full Text
View/download PDF

48. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Author

Coiffier, Bertrand, Osmanov, Evgenii A, Hong, Xiaonan, Scheliga, Adriana, Mayer, Jiri, Offner, Fritz, Rule, Simon, Teixeira, Adriana, Walewski, Jan, de Vos, Sven, Crump, Michael, Shpilberg, Ofer, Esseltine, Dixie-Lee, Zhu, Eugene, Enny, Christopher, Theocharous, Panteli, van de Velde, Helgi, Elsayed, Yusri A, and Zinzani, Pier Luigi

Published
2011
Full Text
View/download PDF

49. MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis

Author

Weissman, Ran, primary, Diamond, Eli L., additional, Haroche, Julien, additional, Durham, Benjamin H., additional, Cohen, Fleur, additional, Buthorn, Justin, additional, Amoura, Zahir, additional, Emile, Jean-François, additional, Mazor, Roei D., additional, Shomron, Noam, additional, Abdel-Wahab, Omar I., additional, Shpilberg, Ofer, additional, and Hershkovitz-Rokah, Oshrat, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results